CRISPR Therapeutics CRSP Return on equity

Return on equity at other companies

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

Intellia TherapeuticsNTLA

-56.3%-1.5pp

Allogene TherapeuticsALLO

-52.3%-5.7pp

Beam TherapeuticsBEAM

-47.1%—

Sana BiotechnologySANA

-147.4%-2,468pp

Design Therapeutics, Inc.DSGN

-31.3%+19.5pp

FAQ

What is CRISPR Therapeutics's return on equity?

CRISPR Therapeutics (CRSP) reported return on equity of -31.2% in Q1 2026.

How has CRISPR Therapeutics's return on equity changed year-over-year?

CRISPR Therapeutics's return on equity decreased by 58.3% year-over-year, from -19.7% to -31.2%.

What is the long-term trend for CRISPR Therapeutics's return on equity?

Over 3 years (2020 to 2025), CRISPR Therapeutics's return on equity has grown at a 4.0% compound annual growth rate (CAGR), from -26.8% to -30.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.